
June 3 (Reuters) - Johnson & Johnson JNJ.N:
JOHNSON & JOHNSON LEADS WITH FIRST PARP INHIBITOR COMBO TO IMPROVE EFFICACY IN PATIENTS WITH HRR-ALTERED MCSPC
JOHNSON & JOHNSON - 50% REDUCTION IN DISEASE PROGRESSION IN BRCA-ALTERED MCSPC
JOHNSON & JOHNSON - PHASE 3 AMPLITUDE STUDY SHOWS AKEEGA DELAYS CANCER PROGRESSION
JOHNSON & JOHNSON - PHASE 3 AMPLITUDE STUDY MEETS PRIMARY ENDPOINT OF RPFS